Atai advances oral psychedelic in depression
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, the FDA’s recent rejection of an MDMA therapy hasn’t seemed to deter some other companies from moving ahead with psychedelics studies. We discuss that, and also some big policy developments that are coming this week.
Read Original Article: Atai advances oral psychedelic in depression »
